Minerva Neurosciences Future Growth
Future criteria checks 0/6
Minerva Neurosciences is forecast to grow earnings and revenue by 12.9% and 70.7% per annum respectively while EPS is expected to grow by 27.3% per annum.
Key information
12.9%
Earnings growth rate
27.3%
EPS growth rate
| Biotechs earnings growth | 23.2% |
| Revenue growth rate | 70.7% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 23 Feb 2024 |
Recent future growth updates
Recent updates
Minerva says FDA declined to accept marketing application for schizophrenia drug
Oct 17Minerva Neurosciences: Biotech On The Move
Aug 29Minerva stock rises on filing for FDA approval of schizophrenia therapy
Aug 22We're Hopeful That Minerva Neurosciences (NASDAQ:NERV) Will Use Its Cash Wisely
Jun 22
Is Minerva Neurosciences (NASDAQ:NERV) In A Good Position To Deliver On Growth Plans?
Jan 26Here's Why We're Not Too Worried About Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Situation
Oct 02Minerva Neurosciences' (NASDAQ:NERV) Shareholders Are Down 59% On Their Shares
Mar 03What You Need To Know About Minerva Neurosciences, Inc.'s (NASDAQ:NERV) Investor Composition
Jan 27We're Keeping An Eye On Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Rate
Dec 23
A Potential Trade Arises On Minerva
Dec 09A Look At Minerva Neurosciences' (NASDAQ:NERV) Share Price Returns
Nov 18Minerva Neurosciences EPS beats by $0.03
Nov 02Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 20 | -104 | N/A | N/A | 1 |
| 12/31/2025 | N/A | -55 | N/A | N/A | 1 |
| 12/31/2024 | N/A | -32 | N/A | N/A | 1 |
| 12/31/2023 | N/A | -30 | -15 | -15 | N/A |
| 9/30/2023 | N/A | -28 | -13 | -13 | N/A |
| 6/30/2023 | N/A | -27 | -18 | -18 | N/A |
| 3/31/2023 | N/A | -29 | -19 | -19 | N/A |
| 12/31/2022 | N/A | -32 | -25 | -25 | N/A |
| 9/30/2022 | N/A | -47 | -25 | -25 | N/A |
| 6/30/2022 | N/A | -49 | -24 | -24 | N/A |
| 3/31/2022 | N/A | -51 | -25 | -25 | N/A |
| 12/31/2021 | N/A | -50 | -25 | -25 | N/A |
| 9/30/2021 | N/A | -36 | -27 | -27 | N/A |
| 6/30/2021 | N/A | -35 | -28 | -28 | N/A |
| 3/31/2021 | 41 | 5 | -30 | -30 | N/A |
| 12/31/2020 | 41 | 2 | -34 | -34 | N/A |
| 9/30/2020 | 41 | -21 | -41 | -41 | N/A |
| 6/30/2020 | 41 | -27 | -40 | -40 | N/A |
| 3/31/2020 | N/A | -69 | -43 | -43 | N/A |
| 12/31/2019 | N/A | -72 | -43 | -43 | N/A |
| 9/30/2019 | N/A | -55 | -39 | -39 | N/A |
| 6/30/2019 | N/A | -54 | -40 | -40 | N/A |
| 3/31/2019 | N/A | -54 | -41 | -41 | N/A |
| 12/31/2018 | N/A | -50 | -42 | -42 | N/A |
| 9/30/2018 | N/A | -37 | -41 | -41 | N/A |
| 6/30/2018 | N/A | -36 | -6 | -6 | N/A |
| 3/31/2018 | N/A | -33 | -2 | -2 | N/A |
| 12/31/2017 | N/A | -32 | 3 | 3 | N/A |
| 9/30/2017 | N/A | -41 | N/A | 3 | N/A |
| 6/30/2017 | N/A | -38 | N/A | -26 | N/A |
| 3/31/2017 | N/A | -34 | N/A | -26 | N/A |
| 12/31/2016 | N/A | -31 | N/A | -26 | N/A |
| 9/30/2016 | N/A | -30 | N/A | -23 | N/A |
| 6/30/2016 | N/A | -28 | N/A | -24 | N/A |
| 3/31/2016 | N/A | -29 | N/A | -25 | N/A |
| 12/31/2015 | N/A | -27 | N/A | -24 | N/A |
| 9/30/2015 | N/A | -26 | N/A | -23 | N/A |
| 6/30/2015 | N/A | -47 | N/A | -44 | N/A |
| 3/31/2015 | N/A | -60 | N/A | -40 | N/A |
| 12/31/2014 | N/A | -57 | N/A | -36 | N/A |
| 9/30/2014 | N/A | -52 | N/A | -32 | N/A |
| 6/30/2014 | N/A | -25 | N/A | -5 | N/A |
| 3/31/2014 | N/A | -6 | N/A | -3 | N/A |
| 12/31/2013 | N/A | -3 | N/A | -2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NERV is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NERV is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NERV is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NERV is forecast to have no revenue next year.
High Growth Revenue: NERV is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NERV's Return on Equity is forecast to be high in 3 years time